Pharma Manufacturing: Meeting Annex I with Precision Machining for Safer Sterile Drug Production

Pharma Manufacturing: Meeting Annex I with Precision Machining for Safer Sterile Drug Production

Pharmaceutical manufacturers are under increasing pressure to deliver sterile, high-quality medicines in smaller batches and faster cycles. As pharma manufacturing evolves evolves, regulatory demands have intensified especially following the 2023 revision of EU GMP Annex I, which places new emphasis on contamination control strategies, improved traceability, and minimizing human intervention throughout production. According to American Pharmaceutical Review,the updated guidelines specifically call for technologies that reduce human involvement and support robust contamination control. This requires manufacturers to rethink how precision machining and mechanical component design support advanced containment. So how can manufacturers ensure safe, efficient, and scalable filling operations, especially when the stakes are patient lives? On this episode of Exceeding Your Benchmark by Benchmark Products, host Michelle Dawn Mooney sits down with Corinna Politi , Head of Export Sales at MPA Technical Devices. They explore how MPA’s precision machining and customizable dosing components are enabling safer, more efficient sterile drug manufacturing in line with evolving global regulations.

Sterile Compounding and Contamination Control with Abby Roth

In this episode of Exceeding Your Benchmark, host Michelle Dawn Mooney speaks with Abby Roth, founder of Pure Microbiology, about sterile compounding and contamination control. Abby shares her expertise in microbiology, sterile environments, and best practices in pharmaceutical compounding. The conversation begins with a distinction between traditional drug manufacturing and sterile compounding, highlighting the role of USP 797 guidelines in ensuring drug safety. Abby explains how compounding fills critical gaps in patient care when commercially available medications are not suitable. She also breaks down the three categories of compounded sterile preparations (CSPs) and the importance of beyond-use dates in maintaining drug efficacy. The discussion then shifts to contamination control, emphasizing the role of primary and secondary engineering controls, proper garbing, and hand hygiene in maintaining sterile environments. Abby stresses the importance of environmental monitoring, explaining how facilities track factors like air quality, particle counts, and microbial contamination to ensure safety. Additionally, Abby introduces her travel companion, “Petrie the Penicillium,” a plush microbe, and shares insights into best practices for cleaning and disinfecting sterile compounding areas. She concludes by emphasizing the essential role of compounding in patient care, even with advancements in drug manufacturing. The episode offers valuable insights for professionals in pharmaceutical compounding, microbiology, and regulatory compliance.

Exploring the Fundamentals of Validation in Life Science Manufacturing

In the rapidly evolving domain of life science manufacturing, validation emerges as a cornerstone to ensure that products meet stipulated requirements concerning quality, safety, and efficacy. This pivotal aspect of manufacturing comes to focus as regulatory landscapes shift, mandating stringent compliance to ensure patient safety. In a recent episode of Exceeding Your Benchmark [https://marketscale.com/shows/benchmark-products/], a podcast by Benchmark Products [https://www.benchmarkproducts.com/], host Gabrielle Bejarano [https://www.gabriellebejarano.com/] sits down with Nessiem Samuel [https://www.linkedin.com/in/nessiemsamuel/], Co-Founder and Head of Compliance and Validation at GxP Impact Consulting [https://gxpimpact.com/], to explore the essence and intricacies of validation in life science manufacturing [https://marketscale.com/industries/healthcare/pharmaceutical-manufacturing-is-finally-witnessing-major-transformation-as-new-demands-for-sterility-assurance-reshape-healthcare/]. The discussion spans from delineating the validation process and its criticality in ensuring product safety to the challenges faced by startups and established operations in adhering to validation norms amidst evolving regulations. The episode underscores validation as a multi-faceted process entailing verification to ensure that products align with design specifications, guaranteeing safety and efficacy once they reach the patients. Samuel elaborates on the lifecycle approach to validation, emphasizing the importance of commissioning, qualification, and eventual validation in facility and process aspects. He shares insights on the significance of in-house process validation while suggesting the outsourcing of early commissioning tasks. Samuel also touches on strategies for effectively managing growth in life science manufacturing while ensuring validation and compliance, highlighting the role of robust planning and asset management in this endeavor. For those looking to deepen their understanding of validation's pivotal role in life science manufacturing, this episode is a valuable resource. It offers expert insights into navigating the compliance and validation landscape effectively.

Redefining Contamination Control Practices in Pharmaceutical Manufacturing

Fred Ayers at pharmaceutical manufacturer Eli Lilly discusses the trends in contamination control and regulations surrounding this.

Connecting Data to Improve Your Contamination Control Strategies

Contamination control is absolutely critical in the pharmaceutical industry and includes particulate, microbial, product carryover, chemical, and viral aspects of contamination and often involves proactive, reactive, and supporting aspects. However, regulations, liabilities, and patient health added to the mix create data silos that often form multiple processes and make it difficult to create efficient and effective contamination control strategies (CCS). How can we connect these data silos to create more effective and efficient CCS protocol in the pharma world? On today’s episode of Exceeding Your Benchmark by Benchmark Solutions, host Gabrielle Bejarano speaks with Sheba Zaman, Head of Product Specialists and Training Services at Novatek International, to talk about how pharmaceutical companies can integrate data use in their processes to improve their contamination control strategies, while abiding by compliance standards and protecting their own data security. Bejarano and Zaman also discussed… Challenges in the pharmaceutical industry with managing compliance data How technology can provide visibility in a holistic manner, and the benefits technology can bring in decision-making and trend analysis The predicted evolution of compliance software in the next five to ten years Zaman explained how companies can quell their concerns about cybersecurity: “Cybersecurity is a big concern; data integrity is a big concern. So, companies just do have to make the big investment to mitigate the risks of, for example, cyber security. They need to do a data integrity risk assessment. So, for any solution that they are implementing to go through the data integrity guidance requirements and basically go through the solution and ensure that both your process and your solutions are meeting the data integrity requirements. Go through that validation process.” Sheba Zaman is an experienced Computer Systems Analyst who has worked with Life Sciences information technology. She is Head of Product Specialists and Training Services at Novatek International and was previously Director of Sales, Senior Product Specialist, and Manager of Technical Sales. Zaman also attended Concordia University, where she earned a BS in Computer Science at Marianopolis College, where she earned a DEC in Health Sciences.